Securities code: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) securities abbreviation: Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) Announcement No.: 2022009 Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932)
Announcement of abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Important content tips:
The trading price of Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) (hereinafter referred to as “the company”) stock (securities code ” Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) “, securities abbreviation ” Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) “) has increased by more than 20% for three consecutive trading days (March 9, 2022, March 10, 2022 and March 11, 2022). According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, It belongs to abnormal fluctuation of stock trading.
After the company’s self-examination and sent a letter to inquire about the controlling shareholders and actual controllers, as of the disclosure date of this announcement, there are no major matters that should be disclosed but not disclosed.
Covid-19 antigen detection reagent of the company has submitted an application for registration to the State Drug Administration. The acquisition time of the registration certificate is still uncertain. Investors are reminded to pay attention to relevant investment risks.
1、 Introduction to abnormal fluctuations in stock trading
The trading price of the company has deviated from the closing price for three consecutive trading days (March 9, 2022, March 10, 2022 and March 11, 2022) by more than 20% in total. According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it is an abnormal fluctuation of stock trading.
2、 Description of attention and verification of important issues
In view of the abnormal fluctuation of the company’s shares, the company checked the relevant matters and asked the controlling shareholder and actual controller of the company. The relevant information is explained as follows:
(I) the company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;
(II) there has been no significant change in the company’s business situation and internal and external business environment in the near future;
(III) after verification, the company, the controlling shareholder and the actual controller have no major matters that should be disclosed but not disclosed about the company, or are in the planning stage;
(IV) after verification, Xinyu chenheng investment partnership (limited partnership), the concerted action of the actual controller of the company, reduced 134807 shares of the company on March 11, 2022. The details are as follows:
Name of shareholder: Xinyu chenheng investment partnership (limited partnership)
Number of shares of the company held at the end of last year (shares) 2656420
Transaction period: March 11, 2022
Reduction mode: centralized bidding
Transaction price (yuan / share) 95.23
Number of transactions (shares) 73718
Reduction mode: block trading
Transaction price (yuan / share) 80.51
Number of transactions (shares) 61089
Number of shares held after this change (shares) 0
Except for the above changes in shares, the controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the period of stock change;
(V) through self-examination, the information disclosed by the company in the early stage does not need to be corrected or supplemented;
(VI) through self-examination, the company has no other circumstances in violation of the provisions on fair information disclosure.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that, in addition to the above matters, the company has no undisclosed matters or planning, negotiation, intention and agreement related to the matters that should be disclosed in accordance with the relevant provisions of the Listing Rules of Shenzhen Stock Exchange; The board of directors has not learned that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the trading price of the company’s shares and their derivatives; In addition to the foregoing, there is no need to correct or supplement other information disclosed by the company in the early stage.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions;
2 and March 11, 2022, according to the National Health Protection Committee, after studying, the State Council decided to add the antigen test to the New Coronavirus disease prevention and control mechanism integrated group on the basis of nucleic acid detection, and formulated the “COVID-19 virus antigen detection application plan (Trial Implementation)”. It is mentioned in the plan: when grass-roots medical and health institutions receive personnel with respiratory tract, fever and other symptoms within 5 days, institutions with nucleic acid detection ability should first carry out nucleic acid detection; Antigen detection shall be carried out for those who do not have the ability of nucleic acid detection. Covid-19 nucleic acid detection reagent company mentioned in the plan has been approved in March 2020 and continues to bring sales revenue to the company; Covid-19 antigen detection reagent of the company has submitted an application for registration to the State Drug Administration. The acquisition time of the registration certificate is still uncertain. Investors are reminded to pay attention to relevant investment risks.
3. Since January 2022, covid-19 epidemic has repeatedly occurred in many places in China, and the number of new cases continues to increase. The large-scale covid-19 nucleic acid testing and screening carried out in various places to prevent and control the epidemic has increased the demand for covid-19 nucleic acid testing reagents and services, which is expected to lead to a significant increase in the company’s covid-19 nuclear acid testing reagent orders and related revenue.
At present, the company is unable to predict the specific impact of the above matters on the company’s performance. In the future, with the gradual control of the epidemic, the demand for relevant covid-19 testing products and services is expected to be unsustainable. The company reminds investors to fully understand the stock market risks, pay special attention to the risk factors disclosed in the company’s periodic reports and other disclosed documents, make rational investment and make prudent decisions.
4. At this stage, the company is in the period of preparing the periodic report. The company has disclosed the annual performance forecast for 2021 on January 5, 2022. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 is 130 million yuan – 150 million yuan, an increase of 177.23% – 219.88% over the same period of the previous year.
Prior to the disclosure of this announcement, the company’s undisclosed regular performance information was not provided to a third party other than the accounting firm audited by the company; The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021. The company shall not amend the annual performance forecast for 2021.
5. The board of directors of the company solemnly reminds investors that the information disclosure media designated by the company are securities times, China Securities News and cninfo（ http://www.cn.info.com.cn. ）, all information disclosure of the company shall be subject to the announcement published in the above media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks.
It is hereby announced.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) board of directors
March 14, 2022
